A Multifaceted Approach to Combating Leishmaniasis, a Neglected Tropical Disease

Total Page:16

File Type:pdf, Size:1020Kb

A Multifaceted Approach to Combating Leishmaniasis, a Neglected Tropical Disease OLD TARGETS AND NEW BEGINNINGS: A MULTIFACETED APPROACH TO COMBATING LEISHMANIASIS, A NEGLECTED TROPICAL DISEASE DISSERTATION Presented in Partial Fulfillment of the Requirements for the Degree Doctor of Philosophy from the Graduate School of The Ohio State University By Adam Joseph Yakovich, B.S. ***** The Ohio State University 2007 Dissertation Committee: Karl A Werbovetz, Ph.D., Advisor Approved by Pui-Kai Li, Ph.D. Werner Tjarks, Ph.D. ___________________ Ching-Shih Chen, Ph.D Advisor Graduate Program In Pharmacy ABSTRACT Leishmaniasis, a broad spectrum of disease which is caused by the protozoan parasite Leishmania , currently affects 12 million people in 88 countries worldwide. There are over 2 million of new cases of leishmaniasis occurring annually. Clinical manifestations of leishmaniasis range from potentially disfiguring cutaneous leishmaniasis to the most severe manifestation, visceral leishmaniasis, which attacks the reticuloendothelial system and has a fatality rate near 100% if left untreated. All currently available therapies all suffer from drawbacks including expense, route of administration and developing resistance. In the laboratory of Dr. Karl Werbovetz our primary goal is the identification and development of an inexpensive, orally available antileishmanial chemotherapeutic agent. Previous efforts in the lab have identified a series of dinitroaniline compounds which have promising in vitro activity in inhibiting the growth of Leishmania parasites. It has since been discovered that these compounds exert their antileishmanial effects by binding to tubulin and inhibiting polymerization. Remarkably, although mammalian and Leishmania tubulins are ~84 % identical, the dinitroaniline compounds show no effect on mammalian tubulin at concentrations greater than 10-fold the IC 50 value determined for inhibiting Leishmania tubulin ii polymerization. These results indicate that Kinetoplastid tubulin may present a useful chemotherapeutic target. Ongoing drug development efforts with the dinitroaniline compounds will require that the next generation analogues be analyzed in vitro against not only the parasite but also purified parasite tubulin. Previously, tubulin has been purified from the pathogenic Leishmania amazonensis . There are several drawbacks with utilizing L. amazonensis as a tubulin source, including, low growth densities, expense of growth medium and risk of infection to laboratory personnel. Leishmania tarentolae utilizes the gecko lizard as a host, and does not infect humans. Furthermore, L. tarentolae can be grown to high densities and can be cultured in inexpensive medium. To assess the suitability of L. tarentolae tubulin as a viable alternative to the corresponding protein from L. amazonensis for compound screening, both the α- and β-tubulin genes were sequenced for comparisons with pathogenic species. Both α- and β-tubulin protein sequences are at least 98% identical to sequences from closely related Leishmania species. Additionally, two in vitro experiments were conducted to examine the degree of dinitroaniline binding site congruency between L. amazonensis and L. tarentolae tubulin. IC 50 values, in terms of inhibiting tubulin polymerization, for our lead compound GB-II-5 were 6.7 µM and 6.8 µM for L. amazonensis and L. tarentolae tubulin, respectively. Dissociation constants (K d), determined by fluorescence quenching, were used to compare binding affinities of GB-II-5 for tubulin from both L. amazonensis and L. tarentolae . The K ds for GB-II-5 for L. amazonensis and L. tarentolae were determined to be 1.7 µM and 2.4 µM, iii respectively. These data taken together indicate that tubulin from L. tarentolae is a suitable alternative to tubulin from pathogenic species for drug evaluation. The K ds and IC 50 values determined for numerous GB-II-5 analogues synthesized in our lab against Leishmania tubulin has allowed us to utilize molecular modeling and molecular dynamics to better characterize the dinitroaniline binding site. Although we have learned a great deal about this site using the aforementioned methods, a crystal structure of tubulin with a dinitroaniline bound would yield the most definitive information about the binding site. Traditionally, tubulin has been very difficult to crystallize, due in part to its lack of stability and it’s propensity to polymerize at higher conditions. Recently the crystal structure of vinblastine bound to mammalian tubulin has been elucidated. The authors utilized stathmin, a 17 kDa protein which acts to regulate microtubule dynamics, to sequester tubulin into tetramers and were able to crystallize a tubulin-stathmin complex. It was thought that this approach may be useful for crystallizing Leishmania tubulin. Reports documenting the purification of mammalian stathmin indicate stathmin present in the soluble cell lysate of fetal bovine thymus will effectively inhibit tubulin polymerization by sequestering dimers. Although successful in inhibiting mammalian tubulin polymerization, preliminary attempts to sequester Leishmania tubulin with active stathmin containing fractions from fetal bovine thymus failed to show any activity. The lack of activity was not particularly surprising and it was hypothesized that variations in tubulin between Leishmania and mammals were great enough to prohibit mammalian stathmin from interacting with Leishmania iv tubulin. As such, the next step was an attempt to identify an active stathmin like protein present in Leishmania or the closely related parasite Crithidia fasciculata . Efforts to isolate an active fraction by looking for activity in terms of inhibiting tubulin polymerization, per the protocol for isolating mammalian stathmin, were unsuccessful. It was discovered that upon warming, a dense precipitate formed in the Leishmania soluble cell lysates. Since tubulin requires heat to polymerize, and that polymerization is assessed by monitoring turbidity at 350 nm, the precipitate was preventing us from monitoring tubulin polymerization or the lack thereof. Attempts to remove the precipitate by repeated warming and centrifugation steps failed to decrease baseline levels to those at which tubulin polymerization could be observed. Being as the protein of interest was likely a low molecular weight protein (LMW), size exclusion chromatography was used to fraction the soluble cell lysate by molecular weight. Although this method was useful in separating the proteins present in the cell lysate, and removing the precipitate, the LMW fractions failed to demonstrate any activity against Leishmania tubulin. Concerns that column fractionation may have decreased the stathmin like protein concentration below its active threshold were addressed by concentrating LMW containing fractions. An iCON protein concentrator was used and effectively concentrated LMW containing fractions from 0.53 mg/mL to 2.7 mg/mL. Unfortunately, these concentrated LMW fractions still failed to show activity against tubulin. At this point the search for a Leishmania stathmin like protein was terminated. This work does not prove that there is no stathmin like protein present in Leishmania , however, it indicatess that if there is such a protein present, it likely does not as large of a role in regulating microtubule dynamics as its mammalian counterpart. Perhaps future studies utilizing v coimmunoprecipitation coupled to mass spectrometry will be useful in identifying proteins that associate with and influence Leishmania microtubule dynamics. GB-II-5 is a promising antileishmanial compound, however, it is desirable to have multiple leads due to later stage attrition often seen in the drug development process. As such, our lab has recently purchased the ChemBridge CNS set of 10,000 druglike molecules. A multifaceted approach is being employed with the library whereby compounds were screened both against Leishmania donovani axenic amastigotes and also against purified Leishmania tubulin. Compounds in this library conform to Lipinski’s rule of 5, thus, it is likely that any potential lead compound identified in this screen will possess oral availability. The first stage of the screen against L. donovani axenic amastigotes identified 75 compounds which inhibited parasite growth by 50 % or more at a concentration of 10 µM. The specific activity, in terms of IC 50 , of each hit compound was then determined. Of the 75 identified active compounds, 47 were found to have IC 50 values ≤ 5 µM. Surprisingly, 11 of the originally identified active compounds failed to show activity when they were reevaluated and had IC 50 values > 25 µM. The 47 compounds with IC 50 values ≤ 5 µM were assayed against mammalian Vero cells to determine if they were selectively cytotoxic to Leishmaia cells. Of the 47 compounds, 17 were found to be at least 25-fold selective for inhibiting Leishmania proliferation. These compounds are currently being screened in our infected macrophage assay. The infected macrophage assay allows us to assess the compounds activity in clearing infection from mouse peritoneal macrophages; this vi system more closely mimics in vivo conditions. Furthermore, efforts are currently underway to examine the mechanism of action of some of the active compounds. Hopefully this endeavor will bring us closer to our ultimate goal of producing an orally available, inexpensive antileishmanial chemotherapeutic agent. vii Dedicated to my Parents: Jeffrey and Kathleen Yakovich, For everything I am and all that I have. viii ACKNOWLEDGMENTS First and foremost, I would like to thank
Recommended publications
  • Five Facts About Giardia Lamblia
    PEARLS Five facts about Giardia lamblia Lenka Cernikova, Carmen FasoID, Adrian B. HehlID* Laboratory of Molecular Parasitology, Institute of Parasitology, University of Zurich (ZH), Zurich, Switzerland * [email protected] Fact 1: Infection with Giardia lamblia is one of the most common causes of waterborne nonbacterial and nonviral diarrheal disease G. lamblia (syn. intestinalis, duodenalis) is a zoonotic enteroparasite. It proliferates in an extra- cellular and noninvasive fashion in the small intestine of vertebrate hosts, causing the diarrheal disease known as giardiasis. Virtually all mammals can be infected with G. lamblia, and epide- miological data point to giardiasis as a zoonosis [1]. Infections in humans may be asymptom- atic or associated with diarrhea, malabsorption, bloating, abdominal pain, fatigue, and weight loss. Based on the latest figures provided by WHO, G. lamblia is the third most common agent of diarrheal disease worldwide with over 300 million reported cases per annum, preceded only a1111111111 by rotavirus and Cryptosporidium parvum and hominis in the most vulnerable target group of a1111111111 a1111111111 children under five years of age [2]. The prevalence of giardiasis in humans ranges from 2%± a1111111111 3% in industrialized countries, up to 30% in low-income and developing countries [3]. Giardi- a1111111111 asis was formerly included in the WHO neglected diseases initiative and is directly associated with poverty and poor quality of drinking water [4]. Acute infection develops over a period of three weeks, peaking at eight days post infection. Generally, healthy hosts clear the infection within 2±3 weeks, whereas the occasional chronically infected host shows signs of villus and crypt atrophy, enterocyte apoptosis, and ultimately severe disruption of epithelial barrier func- OPEN ACCESS tion [5].
    [Show full text]
  • In Vitro Screening for Inhibitors of the Human Mitotic Kinesin Eg5 with Antimitotic and Antitumor Activities
    Molecular Cancer Therapeutics 1079 In vitro screening for inhibitors of the human mitotic kinesin Eg5 with antimitotic and antitumor activities Salvatore DeBonis,1 Dimitrios A. Skoufias,1 agents were mainly first isolated from plants. The Vinca Luc Lebeau,2 Roman Lopez,3 Gautier Robin,1 alkaloids, vincristine and vinblastine (isolated from leaves Robert L. Margolis,1 Richard H. Wade,1 of the Madagascar periwinkle plant), are now used to treat and Frank Kozielski1 leukemia and Hodgkin’s lymphoma, whereas paclitaxel 1 2 (Taxol) [originally extracted from the bark of the western Institut de Biologie Structurale, Grenoble, France; Laboratoire yew tree (2)] and its semisynthetic analogue docetaxel de Chimie Organique Applique´e, Centre National de la Recherche Scientifique, Universite´Louis Pasteur, Faculte´de Pharmacie, (Taxotere) are approved for the treatment of metastatic Illkirch, France; and 3Service de Marquage Mole´culaire et de breast and ovarian carcinomas. The success of these natural Chimie Bio-organique, CEA-Saclay, Gif sur Yvette, France products has initiated the development of f30 second- generation tubulin drugs currently in preclinical or clinical development (reviewed in ref. 3). Abstract All antimitotic tubulin agents interfere with the assembly Human Eg5, a member of the kinesin superfamily, plays and/or disassembly of microtubules and produce a char- a key role in mitosis, as it is required for the formation of acteristic mitotic arrest phenotype. Even low paclitaxel a bipolar spindle. We describe here the first in vitro concentrations (f10 nmol/L), with no obvious effect on microtubule-activated ATPase-based assay for the identi- microtubule dynamics, are sufficient to block cells in mito- fication of small-molecule inhibitors of Eg5.
    [Show full text]
  • Giardiasis Importance Giardiasis, a Gastrointestinal Disease Characterized by Acute Or Chronic Diarrhea, Is Caused by Protozoan Parasites in the Genus Giardia
    Giardiasis Importance Giardiasis, a gastrointestinal disease characterized by acute or chronic diarrhea, is caused by protozoan parasites in the genus Giardia. Giardia duodenalis is the major Giardia Enteritis, species found in mammals, and the only species known to cause illness in humans. This Lambliasis, organism is carried in the intestinal tract of many animals and people, with clinical signs Beaver Fever developing in some individuals, but many others remaining asymptomatic. In addition to diarrhea, the presence of G. duodenalis can result in malabsorption; some studies have implicated this organism in decreased growth in some infected children and Last Updated: December 2012 possibly decreased productivity in young livestock. Outbreaks are occasionally reported in people, as the result of mass exposure to contaminated water or food, or direct contact with infected individuals (e.g., in child care centers). People are considered to be the most important reservoir hosts for human giardiasis. The predominant genetic types of G. duodenalis usually differ in humans and domesticated animals (livestock and pets), and zoonotic transmission is currently thought to be of minor significance in causing human illness. Nevertheless, there is evidence that certain isolates may sometimes be shared, and some genetic types of G. duodenalis (assemblages A and B) should be considered potentially zoonotic. Etiology The protozoan genus Giardia (Family Giardiidae, order Giardiida) contains at least six species that infect animals and/or humans. In most mammals, giardiasis is caused by Giardia duodenalis, which is also called G. intestinalis. Both names are in current use, although the validity of the name G. intestinalis depends on the interpretation of the International Code of Zoological Nomenclature.
    [Show full text]
  • Supplementary Information
    Supplementary Information Network-based Drug Repurposing for Novel Coronavirus 2019-nCoV Yadi Zhou1,#, Yuan Hou1,#, Jiayu Shen1, Yin Huang1, William Martin1, Feixiong Cheng1-3,* 1Genomic Medicine Institute, Lerner Research Institute, Cleveland Clinic, Cleveland, OH 44195, USA 2Department of Molecular Medicine, Cleveland Clinic Lerner College of Medicine, Case Western Reserve University, Cleveland, OH 44195, USA 3Case Comprehensive Cancer Center, Case Western Reserve University School of Medicine, Cleveland, OH 44106, USA #Equal contribution *Correspondence to: Feixiong Cheng, PhD Lerner Research Institute Cleveland Clinic Tel: +1-216-444-7654; Fax: +1-216-636-0009 Email: [email protected] Supplementary Table S1. Genome information of 15 coronaviruses used for phylogenetic analyses. Supplementary Table S2. Protein sequence identities across 5 protein regions in 15 coronaviruses. Supplementary Table S3. HCoV-associated host proteins with references. Supplementary Table S4. Repurposable drugs predicted by network-based approaches. Supplementary Table S5. Network proximity results for 2,938 drugs against pan-human coronavirus (CoV) and individual CoVs. Supplementary Table S6. Network-predicted drug combinations for all the drug pairs from the top 16 high-confidence repurposable drugs. 1 Supplementary Table S1. Genome information of 15 coronaviruses used for phylogenetic analyses. GenBank ID Coronavirus Identity % Host Location discovered MN908947 2019-nCoV[Wuhan-Hu-1] 100 Human China MN938384 2019-nCoV[HKU-SZ-002a] 99.99 Human China MN975262
    [Show full text]
  • Leishmaniasis in the United States: Emerging Issues in a Region of Low Endemicity
    microorganisms Review Leishmaniasis in the United States: Emerging Issues in a Region of Low Endemicity John M. Curtin 1,2,* and Naomi E. Aronson 2 1 Infectious Diseases Service, Walter Reed National Military Medical Center, Bethesda, MD 20814, USA 2 Infectious Diseases Division, Uniformed Services University, Bethesda, MD 20814, USA; [email protected] * Correspondence: [email protected]; Tel.: +1-011-301-295-6400 Abstract: Leishmaniasis, a chronic and persistent intracellular protozoal infection caused by many different species within the genus Leishmania, is an unfamiliar disease to most North American providers. Clinical presentations may include asymptomatic and symptomatic visceral leishmaniasis (so-called Kala-azar), as well as cutaneous or mucosal disease. Although cutaneous leishmaniasis (caused by Leishmania mexicana in the United States) is endemic in some southwest states, other causes for concern include reactivation of imported visceral leishmaniasis remotely in time from the initial infection, and the possible long-term complications of chronic inflammation from asymptomatic infection. Climate change, the identification of competent vectors and reservoirs, a highly mobile populace, significant population groups with proven exposure history, HIV, and widespread use of immunosuppressive medications and organ transplant all create the potential for increased frequency of leishmaniasis in the U.S. Together, these factors could contribute to leishmaniasis emerging as a health threat in the U.S., including the possibility of sustained autochthonous spread of newly introduced visceral disease. We summarize recent data examining the epidemiology and major risk factors for acquisition of cutaneous and visceral leishmaniasis, with a special focus on Citation: Curtin, J.M.; Aronson, N.E.
    [Show full text]
  • Leishmania Major Is Not Altered by in Vitro Exposure to 2,3,7,8‑Tetrachlorodibenzo‑P‑Dioxin Vera Sazhnev and Gregory K
    Sazhnev and DeKrey BMC Res Notes (2018) 11:642 https://doi.org/10.1186/s13104-018-3759-x BMC Research Notes RESEARCH NOTE Open Access The growth and infectivity of Leishmania major is not altered by in vitro exposure to 2,3,7,8‑tetrachlorodibenzo‑p‑dioxin Vera Sazhnev and Gregory K. DeKrey* Abstract Objective: The numbers of Leishmania major parasites in foot lesions of C57Bl/6, BALB/c or SCID mice can be signif- cantly reduced by pre-exposure to 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD). One potential mechanism to explain this enhanced resistance to infection is that TCDD is directly toxic to L. major. This potential mechanism was addressed by exposing L. major promastigotes and amastigotes to TCDD in vitro and examining their subsequent proliferation and infectivity. Results: We found no signifcant change in the rate of in vitro L. major proliferation (promastigotes or amastigotes) after TCDD exposure at concentrations up to 100 nM. Moreover, in vitro TCDD exposure did not signifcantly alter the ability of L. major to infect mice, trigger lesion formation, or survive in those lesions. Keywords: Leishmania major, Dioxin, TCDD, Proliferation, Infectivity Introduction Previous studies in this laboratory have found that the Approximately one million new cases of leishmaniasis numbers of L. major parasites in foot lesions of C57Bl/6, occur each year worldwide [1, 2]. Of the various forms, BALB/c or SCID mice can be signifcantly reduced by cutaneous leishmaniasis is the most common, and vis- exposure to 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) ceral leishmaniasis is the most deadly.
    [Show full text]
  • The Cytoskeleton of Giardia Lamblia
    International Journal for Parasitology 33 (2003) 3–28 www.parasitology-online.com Invited review The cytoskeleton of Giardia lamblia Heidi G. Elmendorfa,*, Scott C. Dawsonb, J. Michael McCafferyc aDepartment of Biology, Georgetown University, 348 Reiss Building 37th and O Sts. NW, Washington, DC 20057, USA bDepartment of Molecular and Cell Biology, University of California Berkeley, 345 LSA Building, Berkeley, CA 94720, USA cDepartment of Biology, Johns Hopkins University, Integrated Imaging Center, Baltimore, MD 21218, USA Received 18 July 2002; received in revised form 18 September 2002; accepted 19 September 2002 Abstract Giardia lamblia is a ubiquitous intestinal pathogen of mammals. Evolutionary studies have also defined it as a member of one of the earliest diverging eukaryotic lineages that we are able to cultivate and study in the laboratory. Despite early recognition of its striking structure resembling a half pear endowed with eight flagella and a unique ventral disk, a molecular understanding of the cytoskeleton of Giardia has been slow to emerge. Perhaps most importantly, although the association of Giardia with diarrhoeal disease has been known for several hundred years, little is known of the mechanism by which Giardia exacts such a toll on its host. What is clear, however, is that the flagella and disk are essential for parasite motility and attachment to host intestinal epithelial cells. Because peristaltic flow expels intestinal contents, attachment is necessary for parasites to remain in the small intestine and cause diarrhoea, underscoring the essential role of the cytoskeleton in virulence. This review presents current day knowledge of the cytoskeleton, focusing on its role in motility and attachment.
    [Show full text]
  • The Potential of Pseudomonas Bacteria As Biocontrol Agents Against Multiple Plant Pathogens
    The potential of Pseudomonas bacteria as biocontrol agents against multiple plant pathogens Sophie Elizabeth Clough Doctor of Philosophy University of York Biology September 2020 Abstract Plant pathogenic bacterium Ralstonia solanacearum (the causative agent of bacterial wilt), and plant parasitic nematodes Globodera pallida (white potato cyst nematode) and Meloidogyne incognita (root-knot nematode) have devastating impacts on several economically important crops globally. While these pathogens are traditionally treated with agrochemicals, their use is in decline due to legal restrictions and harmful impacts on the environment. One environmentally- friendly alternative to agrochemicals could be biocontrol, which takes advantage of naturally occurring plant growth-promoting bacteria. While recent studies have shown promising results, there is no clear screening pipeline to identify and validate successful biocontrol strains with broad activity against multiple different pathogen species. This thesis establishes a screening method to identify effective Pseudomonas biocontrol agents to both bacterial and nematode pathogens using a combination of in vitro laboratory assays, comparative genomics, mass spectrometry and greenhouse experiments. It was found that Pseudomonas strains suppressed both pathogens, with strains CHA0, MVP1-4 and Pf-5 showing high activity. Several secondary metabolite clusters were identified and the suppressive role of DAPG, orfamides A and B and pyoluteorin antimicrobials were experimentally verified. Experimental evolution was used to show that R. solanacearum can evolve tolerance to Pseudomonas strains during prolonged exposure in vitro. However, further work is needed to test whether the evolution of tolerance could limit Pseudomonas biocontrol efficiency in the field. High nematode suppression by all Pseudomonas strains was observed in laboratory assays. Moreover, clear behavioural and developmental changes were observed in response to tested individual compounds.
    [Show full text]
  • 2-Amino-1,3,4-Thiadiazoles in Leishmaniasis
    Review Future Prospects in the Treatment of Parasitic Diseases: 2‐Amino‐1,3,4‐Thiadiazoles in Leishmaniasis Georgeta Serban Pharmaceutical Chemistry Department, Faculty of Medicine and Pharmacy, University of Oradea, 29 Nicolae Jiga, 410028 Oradea, Romania; [email protected]; Tel: +4‐0756‐276‐377 Received: 22 March 2019; Accepted: 17 April 2019; Published: 19 April 2019 Abstract: Neglected tropical diseases affect the lives of a billion people worldwide. Among them, the parasitic infections caused by protozoan parasites of the Trypanosomatidae family have a huge impact on human health. Leishmaniasis, caused by Leishmania spp., is an endemic parasitic disease in over 88 countries and is closely associated with poverty. Although significant advances have been made in the treatment of leishmaniasis over the last decade, currently available chemotherapy is far from satisfactory. The lack of an approved vaccine, effective medication and significant drug resistance worldwide had led to considerable interest in discovering new, inexpensive, efficient and safe antileishmanial agents. 1,3,4‐Thiadiazole rings are found in biologically active natural products and medicinally important synthetic compounds. The thiadiazole ring exhibits several specific properties: it is a bioisostere of pyrimidine or benzene rings with prevalence in biologically active compounds; the sulfur atom increases lipophilicity and combined with the mesoionic character of thiadiazoles imparts good oral absorption and good cell permeability, resulting in good bioavailability. This review presents synthetic 2‐amino‐1,3,4‐thiadiazole derivatives with antileishmanial activity. Many reported derivatives can be considered as lead compounds for the synthesis of future agents as an alternative to the treatment of leishmaniasis. Keywords: 2‐amino‐1,3,4‐thiadiazole; neglected tropical diseases; protozoan parasites; Leishmania spp.; antileishmanial activity; inhibitory concentration 1.
    [Show full text]
  • Molecular Characterization of Leishmania RNA Virus 2 in Leishmania Major from Uzbekistan
    G C A T T A C G G C A T genes Article Molecular Characterization of Leishmania RNA virus 2 in Leishmania major from Uzbekistan 1, 2,3, 1,4 2 Yuliya Kleschenko y, Danyil Grybchuk y, Nadezhda S. Matveeva , Diego H. Macedo , Evgeny N. Ponirovsky 1, Alexander N. Lukashev 1 and Vyacheslav Yurchenko 1,2,* 1 Martsinovsky Institute of Medical Parasitology, Tropical and Vector Borne Diseases, Sechenov University, 119435 Moscow, Russia; [email protected] (Y.K.); [email protected] (N.S.M.); [email protected] (E.N.P.); [email protected] (A.N.L.) 2 Life Sciences Research Centre, Faculty of Science, University of Ostrava, 71000 Ostrava, Czech Republic; [email protected] (D.G.); [email protected] (D.H.M.) 3 CEITEC—Central European Institute of Technology, Masaryk University, 62500 Brno, Czech Republic 4 Department of Molecular Biology, Faculty of Biology, Moscow State University, 119991 Moscow, Russia * Correspondence: [email protected]; Tel.: +420-597092326 These authors contributed equally to this work. y Received: 19 September 2019; Accepted: 18 October 2019; Published: 21 October 2019 Abstract: Here we report sequence and phylogenetic analysis of two new isolates of Leishmania RNA virus 2 (LRV2) found in Leishmania major isolated from human patients with cutaneous leishmaniasis in south Uzbekistan. These new virus-infected flagellates were isolated in the same region of Uzbekistan and the viral sequences differed by only nineteen SNPs, all except one being silent mutations. Therefore, we concluded that they belong to a single LRV2 species. New viruses are closely related to the LRV2-Lmj-ASKH documented in Turkmenistan in 1995, which is congruent with their shared host (L.
    [Show full text]
  • Manual for the Diagnosis and Treatment of Leishmaniasis
    Republic of the Sudan Federal Ministry of Health Communicable and Non-Communicable Diseases Control Directorate MANUAL FOR THE DIAGNOSIS AND TREATMENT OF LEISHMANIASIS November 2017 Acknowledgements The Communicable and Non-Communicable Diseases Control Directorate (CNCDCD), Federal Ministry of Health, Sudan, would like to acknowledge all the efforts spent on studying, controlling and reducing morbidity and mortality of leishmaniasis in Sudan, which culminated in the formulation of this manual in April 2004, updated in October 2014 and again in November 2017. We would like to express our thanks to all National institutions, organizations, research groups and individuals for their support, and the international organization with special thanks to WHO, MSF and UK- DFID (KalaCORE). I Preface Leishmaniasis is a major health problem in Sudan. Visceral, cutaneous and mucosal forms of leishmaniasis are endemic in various parts of the country, with serious outbreaks occurring periodically. Sudanese scientists have published many papers on the epidemiology, clinical manifestations, diagnosis and management of these complex diseases. This has resulted in a better understanding of the pathogenesis of the various forms of leishmaniasis and has led to more accurate and specific diagnostic methods and better therapy. Unfortunately, many practitioners are unaware of these developments and still rely on outdated diagnostic procedures and therapy. This document is intended to help those engaged in the diagnosis, treatment and nutrition of patients with various forms of leishmaniasis. The guidelines are based on publications and experience of Sudanese researchers and are therefore evidence based. The guidelines were agreed upon by top researchers and clinicians in workshops organized by the Leishmaniasis Control response at the Communicable and Non-Communicable Diseases Control Directorate, Federal Ministry of Health, Sudan.
    [Show full text]
  • Viewed in Detail
    NEGLECTED TROPICAL DISEASE CHEMOTHERAPY: MECHANISTIC CHARACTERIZATION OF ANTITRYPANOSOMAL DIHYDROQUINOLINES AND DEVELOPMENT OF A HIGH THROUGHPUT ANTILEISHMANIAL SCREENING ASSAY DISSERTATION Presented in Partial Fulfillment of the Requirements for the Degree Doctor of Philosophy from the Graduate School of The Ohio State University By Shanshan He, M.S. ****** Graduate Program in Pharmaceutical Sciences The Ohio State University 2012 Dissertation Committee: Karl A Werbovetz, Ph.D., Advisor Mark E Drew, Ph.D. Co-advisor Werner Tjarks, Ph.D. Juan D D Alfonzo, Ph.D Copyright by Shanshan He 2012 ABSTRACT Human African trypanosomiasis (HAT) and leishmaniasis are identified by the World Health Organization (WHO) as neglected tropical diseases (NTDs), together with Chagas disease and Buruli ulcer. These NTDs mostly affect people in remote or rural area, and there are very limited control and therapeutic options. The investment on research and development against NTDs is insufficient. Human African trypanosomiasis (HAT) is a vector-borne parasitic disease caused by Trypanosoma brucei subspecies. Transmitted by the tsetse fly, the disease mainly affects rural populations in sub-Saharan Africa and is fatal if untreated. New drugs are needed against HAT that are safe, affordable, easy to administer, active against first and second stage disease, and effective against both subspecies of T. brucei (11, 139). From medicinal chemistry investigation in Karl Werbovetz group, several N1-substituted 1,2-dihydroquinoline-6-ols were discovered displaying nanomolar IC50 values in vitro against T. b. rhodesiense and selectivity indexes (SI) up to >18,000 (39). OSU-40 (1- benzyl-1,2-dihydro-2,2,4–trimethylquinolin-6-yl acetate) is selectively potent against T.
    [Show full text]